Cost-effectiveness analysis on Imipenem-Cilastatin Sodium and Meropenem for severe infection

VernacularTitle:亚胺培南/西司他丁钠与美罗培南治疗重症感染的成本-效果分析
Author: Xiuqin WANG ; Senfang KE ; Chunliu ZHANG
Publication Type:Journal Article
Keywords: Imipenem /cilastatin sodium; Meropenem; Severe infection; Cost-efectiveness analysis
From: Clinical Medicine of China 2013;(4):387-389
CountryChina
Language:Chinese
Abstract: Objective To evaluate the economic effects of Imipenem-Cilastatin Sodium and Meropenem for severe infection.Methods The therapeutic effects and costs of the two therapeutic schemes for severe infection were evaluated by using cost-minimization analysis.Results The total effective rates of Imipenemcilastatin group and Meropenem group in the treatment severe infection were 93.33％ (28/30) and 85.71％ (24/28),the difference were not statistically significant (x2 =4.89,P =0.082).The cost-effectiveness ratio (C/E) were 40.35 and 71.69 respectively.The cost of every unit increment of effectiveness for Meropenem group were 312.16 Yuan,more than that of the Imipenem-cilastatin group.Conclusion Cost-effectiveness ratio of Imipenem-cilastatin is superior to that of Meropenem,and Imipenem-cilastatin has obvious pharmacoeconomics advantage over Meropenem for severe infections.